Hidrasec Για Παιδια (Racecadotril)

Hidrasec Για Παιδια is indicated for the short‑term management of acute, non‑bloody diarrhea in children, helping to reduce stool frequency and volume while maintaining hydration.

• Children with acute watery diarrhea caused by viral or bacterial gastroenteritis.
• Cases where oral rehydration therapy is being used alongside symptomatic treatment.
• Situations requiring reduction of intestinal secretions without affecting gut motility.
• Pediatric patients who need an alternative to loperamide due to safety considerations.
• Episodes of travel‑related diarrhea in children where rapid symptom control is desirable.
• Children receiving concomitant oral rehydration salts who require adjunctive antidiarrheal therapy.

• Racecadotril is a pro‑drug that is rapidly converted to the active metabolite thiorphan, which inhibits the enzyme neutral endopeptidase (enkephalinase) in the intestinal mucosa. By preventing the breakdown of endogenous enkephalins, the drug enhances their local action on opioid receptors in the gut wall, leading to reduced secretion of water and electrolytes without altering intestinal motility. This peripheral effect limits stool output while preserving normal bowel function.

Like most antidiarrheal agents, Hidrasec Για Παιδια may cause mild to moderate adverse reactions, most of which are transient.

Common

• Nausea or mild abdominal discomfort, typically occurring shortly after the first dose.
• Transient headache that resolves without intervention.
• Flatulence or mild bloating, often associated with changes in stool frequency.
• Rarely, a mild skin rash or itching at the site of contact.
• Dizziness or light‑headed feeling, generally mild and self‑limiting.
• Mild taste alteration or metallic aftertaste.

Serious

• Allergic reactions such as urticaria, angioedema, or anaphylaxis requiring immediate medical attention.
• Severe constipation that may progress to bowel obstruction if not addressed promptly.

When using Hidrasec Για Παιδια in children, certain precautions should be observed to ensure safe and effective therapy.

• Verify that diarrhea is acute, non‑bloody, and without fever or systemic infection before starting treatment.
• Do not give to children with known allergy to racecadotril or any excipient.
• Avoid use in chronic diarrhea, inflammatory bowel disease, or persistent vomiting.
• Maintain oral rehydration; the drug does not replace fluid replacement.
• Watch for constipation; stop the medication if severe constipation occurs.
• Seek medical advice before use in infants under 3 months or children with metabolic disorders.

Hidrasec Για Παιδια may interact with other medicines; awareness of potential interactions helps prevent reduced efficacy or increased risk.

Avoid

• Concurrent use with potent opioid analgesics, as combined effects on gut motility may be unpredictable.
• Co‑administration with drugs that significantly alter intestinal secretion, such as certain cholera vaccines, may diminish therapeutic benefit.

Use with caution

• Antibiotics that cause diarrhea (e.g., clindamycin) – monitor clinical response closely.
• Antidiarrheal agents containing loperamide – combined use may increase risk of constipation.
• Medications affecting renal function, such as aminoglycosides, may require dosage adjustment of rehydration solutions.
• Probiotic supplements – no known interaction, but clinical effect should be evaluated.